title: Glandular neoplasia and borderline endocervical reporting rates before and after conversion to the SurePath(TM)  liquid-based cytology (LBC) system.
abstract: Reporting rates for glandular neoplasia in 464,754 cervical samples reported at six laboratories in 12-month periods before and after the implementation of Surepath™ LBC processing are compared. The introduction of LBC processing is seen to have resulted in a significant (P = 0.001) increase in the detection rate for endocervical glandular neoplasia (from 2.2 per 10,000 tests to 3.9 per 10,000) while maintaining high levels of reporting specificity. An observed fall in the number of samples reported as showing borderline glandular neoplasia falls short of statistical significance, and the reporting of possible endometrial and 'other' glandular abnormalities appears to be unaffected. The underlying reasons for the observed improvement in detection of endocervical glandular neoplasia are discussed.
authors.affiliation: North East, Yorkshire and The Humber Quality Assurance Reference Centre, Wallsend, Newcastle Upon Tyne, Tyne and Wear, England.
authors.forename: C
authors.initials: C
authors.lastname: Burnley
authors.forename: N
authors.initials: N
authors.lastname: Dudding
authors.forename: M
authors.initials: M
authors.lastname: Parker
authors.forename: P
authors.initials: P
authors.lastname: Parsons
authors.forename: C J
authors.initials: CJ
authors.lastname: Whitaker
authors.forename: W
authors.initials: W
authors.lastname: Young
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000453:epidemiology; D003581:Cytodiagnosis / Q000379:methods; D005260:Female; D006801:Humans; D015994:Incidence; D011933:Reagent Kits, Diagnostic; D014594:Uterine Neoplasms / Q000175:diagnosis*; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis*
chemical_list: D011933:Reagent Kits, Diagnostic